Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse - Episode 4

MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

October 25, 2024

Ajay Chari, MD, Noopur S. Raje, MD, Adriana Rossi, MD, Weill Cornell Medical College, Natalie Callander, MD, Tom Martin, MD

Panelists discuss the importance of minimal residual disease negativity as a primary outcome measure and the treatment strategies for patients who are eligible for transplantation but choose to decline it, including preferred induction regimens for this population.

EP. 1: Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

EP. 2: Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

EP. 3: Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

Now Viewing

EP. 4: MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

EP. 5: Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

EP. 6: Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

EP. 7: Considerations for Use of CAR T-cell Therapy in Multiple Myeloma

EP. 8: CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024

EP. 9: Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers

EP. 10: Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life

Dr Ajai Chari to Dr Raje: What are your thoughts on minimal residual disease negativity as a primary outcome?
Dr Ajai Chari to Dr Rossi: For patients who are eligible for transplantation but decline, what is your treatment approach for this patient population? Do you have a preferred induction regimen?